TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03315091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - AZD1775 administered under fasted conditions
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A - AZD1775 administered under fasted conditions
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD1775 administered under fed conditions.
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD1775 administered under fed conditions.
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor.
Study: NCT00584740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: 10 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457
Study: NCT02856893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 60 or 40 mg daily until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib 60 or 40 mg daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 60 or 40 mg daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg daily until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250mg daily until progression
Study: NCT03965273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full TP
Description: The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light TP
Description: The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
Study: NCT00964080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBP-426/Leucovorin/5-FU
Description: MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
Study: NCT00105053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute-Prostate Cancer Vaccine
Description: Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
Study: NCT02514473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Study: NCT01358279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: A constant current of 2 mA intensity applied for 20 min over C3 or C4
Study: NCT02311101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Given intravesically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Given intravesically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Given intravesically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Given intravesically
Study: NCT02106923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Empagliflozin/2 tablets Metformin XR
Description: Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Empagliflozin/1000 mg Metformin XR
Description: Experimental: high dose Empagliflozin/Metformin XR, FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
Description: Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
Study: NCT02421653

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INERT OIL
Description: Non-iodised evening primrose oil capsule; oral route; once at study start

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INERT OIL
Description: Non-iodised evening primrose oil capsule; oral route; once at study start
Study: NCT02106923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 tablets 5 mg Empagliflozin/750 Metformin XR
Description: Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Empagliflozin/2 tablets Metformin XR
Description: Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Empagliflozin/1000 mg Metformin XR
Description: Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
Study: NCT02134028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous
Study: NCT02503865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
Description: Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication
Description: Vegetable and salt diet
Study: NCT03246594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of oesophageal probe for temperature measurement
Description: The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power limitation of RF generator
Description: no probe utilized; Limit the RF Generator Output to 25W
Study: NCT03730701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention program for stroke
Description: The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
Study: NCT01401244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
Study: NCT03477916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: fecal microbial transplantation (FMT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: fecal microbial transplantation (FMT)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo FMT
Description: Placebo fecal microbial transplantation (FMT)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo FMT
Description: Placebo fecal microbial transplantation (FMT)
Study: NCT02421653

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: INERT OIL
Description: Non-iodised evening primrose oil capsule; oral route; once at study start

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INERT MNP
Description: Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NON-IODISED MNP
Description: Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
Study: NCT02272803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT03477916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic Fiber
Description: combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
Study: NCT02272803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608)
Study: NCT00834561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: 200 mg Tablet
Study: NCT03477916

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotic Fiber
Description: combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cellulose
Description: Cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellulose
Description: Cellulose
Study: NCT00816946

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced education
Description: Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI
Study: NCT03163238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
Study: NCT00077454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00009867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study: NCT00330824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic/steroid combination
Description: 1gtt, 4x/d, 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin/dexamethasone
Description: 1gtt, 4x/days, 15 days
Study: NCT03990948

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sample collection

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sample collection

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sample collection
Study: NCT02333539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence behaviors and recommendations for improvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence behavior that needs improvement is targeted
Study: NCT03742804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral G100
Description: G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
Study: NCT03306771

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Duplex
Description: The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Duplex
Description: The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
Study: NCT03427775

Intervention type: COMBINATION_PRODUCT
Intervention: multimodal perioperative pain protocol (MP3)
Description: administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
Study: NCT02194296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride - lozenge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol hydrochloride - syrup
Study: NCT00834561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: 200 mg Tablet
Study: NCT03674619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior discectomy
Description: Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
Study: NCT04290546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-15 Superagonist (N-803)
Description: -- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-15 Superagonist (N-803)
Description: -- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-15 Superagonist (N-803)
Description: -- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIML NK cell Infusion
Description: (Dose 0 or -1) infused on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIML NK cell Infusion
Description: (Dose 0 or -1) infused on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIML NK cell Infusion
Description: (Dose 0 or -1) infused on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: single dose of lead-in ipilimumab via iv per protocol determined dose
Study: NCT02837484

Intervention type: OTHER
Group type: OTHER
Intervention: NuTech Affinity™ Membrane
Description: NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
Study: NCT03915860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene
Description: Topical Cream
Study: NCT00677053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-442
Description: Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Study: NCT00609362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: one tablet of rosiglitazone 8 milligrams per day for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: One encapsulated placebo pill a day for 14 weeks
Study: NCT01774370

Intervention type: DRUG
Intervention: Pradaxa (Dabigatran etexilate mesilate)
Description: 110 mg or 150 mg b.i.d.
Study: NCT03051009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 25 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 50 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 50 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin ODT 50 μg